Research
Novel Glucagon/GLP-1 Agonist Meets Cardiovascular Safety Endpoint
The Brief
- Survodutide, an investigational glucagon and GLP-1 receptor dual agonist, met a cardiovascular safety endpoint in a trial of patients with obesity.
- Participants had established cardiovascular disease, chronic kidney disease, or increased risk of cardiovascular disease.
- The source reports the drug was safe for these patients; it is not yet an approved therapy.
Why it matters
The result addresses a key safety requirement for new obesity drugs in patients with heart and kidney risk, a population where safety data are critical before wider use.
Who’s affected
- clinicians treating patients with obesity and cardiovascular or kidney disease
- researchers in obesity and metabolic drug development
- #obesity
- #cardiovascular safety
- #glucagon receptor
- #glp-1
- #clinical trial
(MedPage Today) -- Survodutide, an investigational glucagon receptor and GLP-1 receptor dual agonist, was safe for patients with obesity and either established cardiovascular disease (CVD), chronic kidney disease (CKD), or increased risk of CVD...
Timeline
MedPage Today reports that survodutide met the cardiovascular safety endpoint, presented at AHA meeting coverage
MedPageToday.com - medical news for physicians
Novel Glucagon/GLP-1 Agonist Meets Cardiovascular Safety Endpoint